Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties

• US 7,598,273 B2
• Filed: 10/04/2006
• Issued: 10/06/2009
• Est. Priority Date: 10/06/2005
• Status: Active Grant

• Current Assignee: Auspex Pharmaceuticals, Inc. (Teva Pharmaceutical Industries Limited)
• Original Assignee: Auspex Pharmaceuticals, Inc. (Teva Pharmaceutical Industries Limited)
• Inventors: Sarshar, Sepehr, Gant, Thomas G.
• Primary Examiner(s): Morris; Patricia L
• Application Number:
  US11/544,407
• Publication Number:
  US 20070082929A1
• Time in Patent Office: 1,098 Days
• Field of Search: 546/273.7, 514/338
• US Class Current: 514/338
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

Chemical syntheses and medical uses of novel inhibitors of the gastric H⁺, K⁺-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.

Claims

1. A compound of Formula 1

2. The compound of claim 1, wherein said compound contains about 90% or more by weight of the (−

)-enantiomer of said compound and about boo or less by weight of (+)-enantiomer of said compound.

3. The compound of claim 1, wherein said compound contains about 90% or more by weight of the (+)-enantiomer of said compound and about boo or less by weight of (−

)-enantiomer of said compound.

4. The compound of claim 1, wherein said alkyl is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, and tert-butyl.

5. The compound of claim 1, wherein said alkyloxy is selected from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, sec-butoxy, and tert-butoxy.

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, compound together with a with a pharmaceutically acceptable carrier.

10. The pharmaceutical composition of claim 9, wherein said composition is suitable for oral, parenteral, or intravenous infusion administration.

11. The pharmaceutical composition of claim 10, wherein said oral administration comprises administering a tablet or a capsule.

12. The pharmaceutical composition of claim 9, wherein said compound of claim 1 is administered in a dose 0.5 milligram to 80 milligram total daily.

6. A compound selected from the group consisting of:

7. A compound selected from the group consisting of:

8. A compound selected from the group consisting of: